Original Research
Published on 17 Oct 2022
Niraparib-induced STAT3 inhibition increases its antitumor effects
in Molecular and Cellular Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.966492
- 5,062 views
- 6 citations
36 articles related to "Niraparib"
Articles
Original Research
Published on 27 Jul 2023
Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1198585
- 3,478 views
- 2 citations
Case Report
Published on 10 Mar 2022
Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2022.853211
- 2,991 views
- 6 citations
Original Research
Published on 17 Jun 2024
Real-world TRAE association between niraparib and platinum-based chemotherapy
in Gynecological Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1390820
- 2,183 views
- 1 citation
Case Report
Published on 04 Jul 2025
Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
in Gynecological Oncology
Frontiers in Oncology
doi 10.3389/fonc.2025.1542646
- 2,704 views
- 3 citations
Original Research
Published on 25 Mar 2022
Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2022.851246
- 20,456 views
- 75 citations
Systematic Review
Published on 22 Feb 2021
Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
in Women's Cancer
Frontiers in Oncology
doi 10.3389/fonc.2020.573801
- 7,875 views
- 15 citations
Original Research
Published on 24 Oct 2025
PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation
in Cancer Cell Biology
Frontiers in Cell and Developmental Biology
doi 10.3389/fcell.2025.1677261
- 1,804 views
- 1 citation
Systematic Review
Published on 08 Jun 2022
Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis
in Gynecological Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.815265
- 8,066 views
- 18 citations
Original Research
Published on 04 Jan 2023
Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
in Drugs Outcomes Research and Policies
Frontiers in Pharmacology
doi 10.3389/fphar.2022.987337
- 3,999 views
- 10 citations
Case Report
Published on 17 Jun 2024
Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1396606
- 2,500 views
- 2 citations
Case Report
Published on 19 Jan 2023
Exploration of chemotherapy-free regimen after multi-line chemotherapy-induced renal impairment in recurrent ovarian cancer: Case report and literature review
in Gynecological Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.1031045
- 3,760 views
- 3 citations
Original Research
Published on 21 Nov 2024
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma
in Gastrointestinal Cancers: Gastric and Esophageal Cancers
Frontiers in Oncology
doi 10.3389/fonc.2024.1435056
- 2,992 views
- 3 citations
Original Research
Published on 23 Jan 2024
Integrated transcriptome and cell phenotype analysis suggest involvement of PARP1 cleavage, Hippo/Wnt, TGF-β and MAPK signaling pathways in ovarian cancer cells response to cannabis and PARP1 inhibitor treatment
in Cancer Genetics and Oncogenomics
Frontiers in Genetics
doi 10.3389/fgene.2024.1333964
- 4,048 views
- 1 citation
Methods
Published on 23 Mar 2022
Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study
in Gynecological Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.852772
- 7,677 views
- 17 citations
Case Report
Published on 06 Dec 2021
Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
in Pharmacology of Anti-Cancer Drugs
Frontiers in Oncology
doi 10.3389/fonc.2021.603591
- 4,159 views
- 9 citations